---
title: "Lysergide (DT120) in Generalized anxiety disorder: Dosage"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Dosage. Topics: Phase 3 dose: single 100 µg DT120 ODT, Panorama: 50 µg comparator arm, Symptom-triggered open-label redosing in the 40-week extension, Dose selection from the phase 2b dose-finding trial, and 2 further topics. 6 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/dosage"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Phase 3 dose: single 100 µg DT120 ODT

> “Single dose regimen is being studied in pivotal clinical trials with primary and secondary outcome measures through 12 weeks after administration.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “Voyage is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single 100 µg dose of DT120 ODT versus placebo in adults with generalized anxiety disorder (GAD).”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.10.1-2"></a>

### Panorama: 50 µg comparator arm

> “randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo, with the 50 µg arm included to help mitigate functional unblinding.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.10.1-3"></a>

### Symptom-triggered open-label redosing in the 40-week extension

> “during which participants may be eligible to receive up to four additional doses of DT120 ODT 100 μg based on symptom severity, for a total study duration of approximately 56 weeks.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Open-label DT120 ODT 100 μg ≥4 weeks after last dose and ≤4 weeks of meeting threshold”
> “Max of 4 doses in extension period”
> “Total of up to 5 doses over 52-week period with final dose no later than week 50.”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “Eligible for open-label treatment if HAM-A ≥16”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.1.2.10.1-4"></a>

### Dose selection from the phase 2b dose-finding trial

> “In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).”
> “The 100-µg dose of MM120 was determined to be optimal, demonstrating a statistically significant change in GAD that exceeded the changes seen with lower MM120 doses or with placebo.”
> “The 200-µg dose of MM120 was associated with more frequent AEs without improvements in efficacy.”
> “These findings support the selection of 100-µg dose of MM120 for pivotal trials to assess its efficacy, durability, and safety in the treatment of GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Considering the efficacy and safety profile observed in the phase 2b study, MM120 100μg (freebase-equivalent) is considered an acceptable therapeutic dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.10.1-5"></a>

### Dose-response in healthy participants above 100 µg

> “Therefore, LSD doses higher than 100 µg produced no further increases in good drug effects but more ego dissolution and anxiety.”
> “These results may assist with dose finding for future LSD research.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.10.1-6"></a>

### Characterization of the 100 µg dose in an independent drug review

> “The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.”
> “However, DT120 should not be described as microdosing or modified release: 100 micrograms is a perceptible psychedelic dose, whereas controlled microdosing studies have generally used 5-20 micrograms, and the pivotal product is described publicly as a fast-dissolving orally disintegrating tablet.”

Source: [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
